VentriPoint Diagnostics Ltd., a Seattle-based provider of diagnostic tools to monitor patients with heart disease, announced it raised total proceeds of $1,052,317 in debenture financing. Health Canada has granted licensed approval for VentriPoint’s diagnostic tool which is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The diagnostic tool, together with its associated online service, is being developed for a variety of heart related diseases, including congenital heart disease and pulmonary hypertension.
Related external links (will open a new window):
Related WTC links:
– end of post –